S&P Global Agrees to Acquire With Intelligence from Motive Partners for $1.8 Billion, Establishing Its Leadership in Private Markets Intelligence

S&P Global (NYSE: SPGI) today announced an agreement with a group led by majority investor Motive Partners, a private ...

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...